Commentary On: The Use of Burosumab to Treat Autosomal-recessive Hypophosphatemic Rickets Type 2: Rationale and a First Clinical Experience
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Rutsch F, Vaingankar S, Johnson K, Goldfine I, Maddux B, Schauerte P
. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol. 2001; 158(2):543-54.
PMC: 1850320.
DOI: 10.1016/S0002-9440(10)63996-X.
View
2.
Nitschke Y, Yan Y, Buers I, Kintziger K, Askew K, Rutsch F
. ENPP1-Fc prevents neointima formation in generalized arterial calcification of infancy through the generation of AMP. Exp Mol Med. 2018; 50(10):1-12.
PMC: 6204430.
DOI: 10.1038/s12276-018-0163-5.
View
3.
Ferreira C, Kintzinger K, Hackbarth M, Botschen U, Nitschke Y, Mughal M
. Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies. J Bone Miner Res. 2021; 36(11):2193-2202.
PMC: 8595532.
DOI: 10.1002/jbmr.4418.
View
4.
Stern R, Levi D, Gales B, Rutsch F, Salusky I
. Correspondence on "Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)" by Ferreira et al. Genet Med. 2021; 23(10):2006-2007.
DOI: 10.1038/s41436-021-01228-4.
View
5.
Parolin M, Partigiani N, Benetti E, Longo G, Vidal E
. The use of burosumab to treat autosomal-recessive hypophosphatemic rickets type 2: rationale and a first clinical experience. J Nephrol. 2024; 37(5):1371-1374.
DOI: 10.1007/s40620-023-01884-6.
View